GALT

Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company based in Norcross, Georgia, that is pioneering the development of innovative therapies aimed at treating fibrotic diseases, certain cancers, and other severe medical conditions. Leveraging its proprietary technology centered on galectin proteins, the company is strategically positioned to target critical pathways in disease progression and inflammation, addressing serious unmet medical needs. With a promising pipeline and a commitment to advancing its therapeutic candidates towards FDA approval, GALT aspires to significantly improve treatment options for patients facing some of the most challenging health issues today.